ArticleWorld journal of urology2026
Protocol-driven botulinum toxin injections for pediatric neurogenic bladder: long-term continence and bladder outcomes supporting its role as a minimally invasive alternative to augmentation cystoplasty.
Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the long-term efficacy, continence outcomes, and videourodynamic changes associated with protocol-driven intra-detrusor botulinum toxin A injections (BTA) in children and adolescents with neurogenic bladder. PATIENTS AND
methodsWe retrospectively reviewed all patients with neurogenic bladder who underwent BTA between 2011 and 2024 at a large referral center. Data collected included demographics, continence status, and VUDS parameters (capacity, compliance, and detrusor overactivity) pre- and post-injection.
resultsAmong 120 patients (63 male), the most common diagnosis was myelomeningocele (n = 88, 73.3%). The median age at first injection was 10.1 years (IQR 8.6). Patients received a median of three injections and were followed for a median of 4.9 years (IQR 6.9) after the first BTA injection. The median overall institutional follow-up from diagnosis was 15 years (IQR 6.8). Of the 107 patients with available symptom data, 96 (89.7%) reported improved continence. Among these, 37 (34.6%) achieved complete resolution and discontinued oral medications, while 49 (45.8%) required ongoing oral agents to maintain continence. An additional 10 patients (9.3%) reported partial improvement with persistent leakage despite BTA and oral therapy but chose to continue injections. A small subset experienced no (n = 5, 4.7%) or diminishing (n = 6, 5.6%) benefit over time. Bladder capacity increased by 27% (p < 0.01), and both compliance and detrusor overactivity significantly improved post-injections, which were typically repeated every 3-6 months. Reported complications were mild and infrequent, including urinary tract infections (11%), constipation (2%), and hematuria (3%).
conclusionsBTA injections are a safe and effective treatment option for most pediatric and adolescent neurogenic bladder patients who would otherwise be considered candidates for augmentation cystoplasty. Repeated injections appear to provide sustained improvement in continence and bladder dynamics, supporting their role as a minimally invasive strategy for long-term bladder management in this population.
Indexed as
Identifiers
42319465What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.